The arachidonic acid (AA) cascade produces eicosanoids, such as prostaglandins (PGs), that regulate physiological and pathological functions. Although various nonsteroidal anti-inflammatory drugs have been developed, blocking upstream components (cyclooxygenase-1 and -2) of the AA cascade leads to severe side effects, including gastrointestinal ulcers and cardiovascular events, respectively, due to the complexity of the AA cascade. Here, using an AA cascade-targeted lipidomics approach, we report that microsomal PGE synthase 1 (mPGES-1) plays a key role in experimental autoimmune encephalomyelitis (EAE). Eicosanoids (mainly PGD 2) are produced constitutively in the spinal cord of naive mice. However, in EAE lesions, the PGE 2 pathway is favored and the PGD2, PGI2, and 5-lipoxygenase pathways are attenuated. Furthermore, mPGES-1 ؊/؊ mice showed less severe symptoms of EAE and lower production of IL-17 and IFN-␥ than mPGES-1 ؉/؉ mice. Expression of PGE2 receptors (EP1, EP2, and EP4) was elevated in EAE lesions and correlated with clinical symptoms.
M
ultiple sclerosis (MS) is the most prevalent autoimmune disorder of the central nervous system (CNS), with neurological symptoms caused by inflammation and demyelination (1) .
Studies of experimental autoimmune encephalomyelitis (EAE), an animal model for MS, have shown that autoreactive T cells secreting IL-17 (T H 17 cells) and IFN-␥ (T H 1 cells) are involved in EAE/MS pathogenesis (2-4).
In an effort to understand and treat this complex disease, lipids have emerged as one of the targets for developing drugs. Membrane lipids have been identified as autoantigens in MS and EAE pathologies (5) . In addition to membrane components, lipids play roles in cell-cell interaction as autacoids. Arachidonic acid (AA) is released from membrane glycerophospholipids by the action of cytosolic phospholipase A 2 ␣ (cPLA 2 ␣) (6, 7). Released AA is further converted into prostaglandins (PGs), leukotrienes (LTs), lipoxins, and hydroxy-eicosatetraenoic acids (HETEs), collectively termed eicosanoids, by cyclooxygenases (COXs), lipoxygenases (LOs), and terminal enzymes (8) . Involvement of eicosanoids and related lipid mediators has been reported in EAE, collagen-induced arthritis, and other immunological disorders (6, 7, 9) . Previously, we and others clearly demonstrated the importance of cPLA 2 ␣ in EAE pathology by genetically and pharmacologically ablated mouse studies (10) (11) (12) . Furthermore, cPLA 2 ␣ expression and activities were up-regulated in the spinal cords (SCs) of EAE mice (13) . However, it remains totally elusive which eicosanoids downstream of cPLA 2 ␣ are involved in the EAE induction and exacerbation. Miyamoto et al. (14) demonstrated that COX-2 Ϫ/Ϫ mice develop EAE with comparable severity to wild-type control mice, while indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), prevents EAE. However, all mice treated with effective doses of indomethacin died of gastrointestinal bleeding (14) . On the other hand, 5-LO Ϫ/Ϫ or 12/15-LO Ϫ/Ϫ mice developed more severe EAE than control wild-type mice (15) , while pharmacological studies showed different results (12) . Previous sketchy studies to focus on individual eicosanoids in EAE or MS patients have obvious limitations, as Ͼ20 different eicosanoids are produced by the concerted actions of cPLA 2 ␣ and downstream enzymes (Fig. S1 ) (16) (17) (18) . To overcome such complexity and some controversy, we evaluated the cascade in the SCs of naive and EAE mice by the nonbiased top-down approach (AA cascade-targeted lipidomics and transcriptomics) and confirmed the results from knockout studies.
the AA cascade dynamics during EAE (Fig. 2) . Approximately 90% of the eicosanoids in the SCs of naive mice were derived from the COX pathway (Fig. S3) . The rank order of eicosanoids in the SCs of naive mice was the following: PGD 2 and metabolites Ͼ PGE 2 and metabolites Ͼ6-keto-PGF 1␣ Ͼ PGF 2␣ and metabolites Ͼ cysteinyl LTs Ͼ11-HETE Ͼ12-HETE Ͼ15-HETE Ͼ thromboxane B 2 (TXB 2 ) Ͼ 5-HETE Ͼ8-HETE Ͼ LTB 4 (Fig. 2 A) . Cluster analysis demonstrated pathway-dependent fluctuations in the AA cascade, such as COX (clusters I and III) and LO (cluster II), during the course of EAE (Fig. 2B) . Eicosanoids belonging to cluster I, such as PGD 2 and 6-keto-PGF 1␣ , were markedly suppressed in the acute phase and returned to the basal levels in the chronic phase ( Fig. 2  A and B) . Suppression of these metabolites was probably caused by the fluctuation of L-PGDS and PGIS, respectively (Fig. 1B) . 5-LO metabolites (LTB 4 , LTC 4 , LTD 4 , and 5-HETE) belonging to cluster II considerably diminished during the disease course ( Fig. 2 A and  B) , although the up-regulation of 5-LO pathway components were remarkable (Fig. 1B) . In the cluster III, the levels of PGE 2 and 13, 14-dihydro-15-keto-PGE 2 (DHK-PGE 2 , a major tissue metabolite of PGE 2 ) were increased, thereby making them the major eicosanoids in acute phase SCs instead of PGD 2 and its metabolites (Fig. 2 A) . In the chronic phase of EAE, the level of PGE 2 remained higher than in naive mice (Fig. 2 A) . Among PGESs, only mPGES-1 was up-regulated in the SCs of EAE mice (Fig. 1B) , suggesting that this is the key enzyme for the PGE 2 accumulation in EAE lesions. Cluster IV consists of only platelet-activating factor (PAF), which is structurally distinct from the eicosanoids. We previously reported that PAF exacerbates inflammation in the chronic phase of EAE by the enhancement of phagocytosis in microglia/macrophages and subsequent production of TNF-␣ (19). Furthermore, there was a strong correlation between PAF levels and clinical scores of EAE (13, 19) . However, in the current study, no eicosanoid was correlated with the clinical scores of EAE. Although we also measured eicosanoid levels in the spleen and plasma, there were only a few fluctuations in these samples (Fig. S4) . These results suggest that the AA cascade was strictly regulated in the SCs of naive mice and this regulation was disrupted by EAE pathology.
Next, correlations between the pathways were analyzed to understand the selectivity of the downstream pathways in the AA cascade (Fig. 2C, Fig. S5 , and Table S1 ), because the cluster analysis revealed the pathway-dependent fluctuations. The COX pathway (PGs, TXs, and 11-HETE) correlated with the 5-LO pathway (LTs and 5-HETE) in naive mice (Fig. 2C ). Of note, AA metabolism was shifted into the COX pathway, rather than the 5-LO pathway, in the acute phase of EAE (Fig. 2C) . Within the COX pathway, the PGE 2 pathway was correlated with both the PGD 2 and PGI 2 pathways in naive mice (Fig. S5 and Table S1 ). After the induction phase, the PGE 2 pathway was correlated with both the PGD 2 and PGI 2 pathways, while PGE 2 production was facilitated, as shown by the small slope (Fig. S5) . Correlations between other pathways (Table  S1 ), such as the PGD 2 and PGI 2 pathways (Fig. S5) , were largely conserved throughout the disease course, as indicated by the stable slopes. Taken together, the COX-mPGES-1-PGE 2 -EP axis may aggravate EAE pathology.
mPGES-1 Exacerbates EAE Pathology Through TH1 and TH17 Cytokine
Production. To further elucidate the roles of PGE 2 pathway in EAE, we particularly focused on mPGES-1, a key enzyme responsible for PGE 2 production in inflammation (20) (21) (22) . In EAE lesions, mPGES-1 was colocalized with F4/80, a marker for macrophages, but not with CD4 (Fig. 3A) . PGE 2 production in SCs of EAE mice was completely blocked by disruption of the mPGES-1 gene (Fig.  3B ), suggesting that PGE 2 production in EAE lesions depends on mPGES-1 expressed in macrophages/microglia. The clinical course of EAE in mPGES-1 Ϫ/Ϫ mice was less severe than in mPGES-1 ϩ/ϩ mice ( Fig. 3C) , consistent with the lower cumulative scores in mPGES-1 Ϫ/Ϫ mice (Table S2) . To understand the mechanisms underlying the attenuated symptoms of EAE in mPGES-1 Ϫ/Ϫ mice, proliferation and cytokine production of T cells in response to the MOG peptide were investigated (Fig. 3 D-F ). When stimulated with the MOG peptide, cells isolated from lymph nodes (LNs) of immunized mPGES-1 ϩ/ϩ and mPGES-1 Ϫ/Ϫ mice proliferated similarly (Fig. 3D) . However, LN cells from mPGES-1 Ϫ/Ϫ mice produced significantly lower levels of cytokines (TNF-␣, IFN-␥, IL-6, and IL-17) than mPGES-1 ϩ/ϩ mice (Fig. 3E ). Flow cytometry of MOG -treated CD4 ϩ T cells also revealed that IFN-␥ and IL-17 production in mPGES-1 Ϫ/Ϫ mice was reduced (Fig. 3F) . Taken together, PGE 2 derived from mPGES-1 appears to support T H 1 and T H 17 cytokine production in EAE lesions. 
mPGES-1 Is Expressed in Human MS Lesions.
To investigate whether the mPGES-1 is a therapeutic target in MS patients, we examined autopsy brain tissues obtained from MS patients (Fig. 4 ). In accordance with murine EAE (Fig. 3A) , immunohistochemistry on MS lesions revealed the overt expression of mPGES-1 protein (Fig.  4 A, B , D, and E) in CD68 ϩ macrophages (Fig. 4 G-Q) . Immunoreactivity of mPGES-1 was not detected with antigen-absorbed Ab (Fig. 4 C and F) . These data suggest that not only murine EAE, but also human MS pathology seems to be influenced by the mPGES-1-PGE 2 axis of the AA cascade.
Discussion
In the present study, we provided a comprehensive overview of the AA cascade dynamics in EAE lesions and determined the roles of mPGES-1 and PGE 2 in EAE. By the AA cascadetargeted lipidomics approach, we found that the PGE 2 pathway is favored and the PGD 2 , PGI 2 , and 5-LO pathways are attenuated. Correlation analysis imply that the AA producing enzyme cPLA 2 ␣ possibly passes more AA to the COX than the 5-LO pathway in EAE, because the sequential actions of eicosanoidsynthesizing enzymes are regulated spatially and temporally in the cells, the so-called functional coupling (16) (17) (18) . Likewise, PGH 2 , a common precursor of PGs, appears to be selectively consumed by the PGE 2 pathway rather than the PGI 2 and PGD 2 pathways, thereby producing PGE 2 in the SCs of EAE mice. The symptoms of EAE in COX-2 Ϫ/Ϫ mice were comparable to those of wild-type controls and administration of indomethacin, a nonselective COX inhibitor, prevented development of the disease (14) . We found that COX-2 expression was substantially upregulated in the SCs of EAE mice from the induction phase (Fig.  1B) . The absolute number of microglia/macrophages increased before the onset and throughout the disease course (23), and COX-2 is generally induced by the inflammatory mediators in these cells (24) , implying that the up-regulation of COX-2 depended on these cells. In human MS, Rose et al. reported the COX-2 expression in microglia/macrophages of MS lesions (25) . We demonstrated here that COX-1 mRNA expression is up-regulated in the SCs of EAE mice (Fig. 1B ) and is correlated with clinical symptoms (Fig. S2 ). Deininger and Schluesener showed the constitutive expression of COX-1 in the microglia/macrophages of rat brain and an elevation of its expression levels in the cells with the progression of EAE (26) . Further studies are needed to disclose the functions of COX-1 and COX-2 in EAE pathology.
Among the eicosanoids examined, only the PGE 2 level was significantly elevated in the SCs of EAE mice (Fig. 2) . This up-regulation seems to depended on the mPGES-1 expressed in the microglia/macrophages of EAE lesions, because the PGE 2 production was almost completely suppressed in mPGES-1 Ϫ/Ϫ mice (Fig.  3B ). The expression of EP1, EP2, and EP4 was altered depending on the disease severity ( Fig. 1B and Fig. S2 ). Therefore, these EPs are candidates for the downstream effectors of PGE 2 . Indeed, the exogenous and endogenous PGE 2 activates EP2 and EP4 on antigen presenting cells to stimulate expression of IL-23 and IL-6, resulting in a shift toward T H 17 responses (27) (28) (29) (30) . PGE 2 synergized with IL-23 in expanding human T H 17 cell (31) and directly promoted differentiation of human and murine T H 17 cells through EP2/EP4 signaling (32 (30) . T cells appear to encounter the autoantigens mainly in the peripheral lymphoid organs in the induction phase, and then in inflammatory foci of CNS in the acute and chronic phases. The levels of PGE 2 in the spleen were unchanged during the disease course (Fig. S4) , whereas those in the SCs were drastically elevated in wild-type mice (Fig. 2) . Furthermore, the EAE pathology of mPGES-1 Ϫ/Ϫ mice was attenuated in the chronic phase. These results imply that EP4-expressing T cells are affected by PGE 2 in the CNS rather than in peripheral lymphoid organs. We showed that the mPGES-1 deficiency abrogated the T H 1 and T H 17 cytokine production in EAE (Fig. 3 E and  F) , suggesting that PGE 2 produced by microglia/macrophages in inflammatory foci may aggravate EAE by promoting the differentiation of T H 1 and the expansion of T H 17 cells through these EPs (Fig. 5) .
We found that the PGIS expression was essentially diminished in EAE-induced C57BL/6 mice, resulting in a significant decrease of 6-keto-PGF 1␣ levels in the acute phase of EAE (Fig. 2) . Because PGI 2 enhances endothelial barrier function (34), PGI 2 seems to protect mice from EAE by suppressing the inflammatory cell infiltration. Several reports showed that loss of mPGES-1 results in the rediversion of a substrate PGH 2 to other prostanoids, like PGI 2 , which may affect the physiological and pathophysiological conditions of mPGES-1 Ϫ/Ϫ mice (35-37). Therefore, it is possible that the amelioration of EAE in mPGES-1 Ϫ/Ϫ mice is due to the upregulation of PGI 2 levels (Fig. S6) . On the other hand, the collageninduced arthritis was aggravated by the PGI 2 -IP axis (38) , raising another possibility that the PGI 2 is an exacerbating factor in T H 1 and T H 17 immune responses and EAE pathology. The roles of PGI 2 in EAE pathology remain controversial, and further studies are needed.
Reduction in PGD 2 levels in the acute phase and its recovery in the chronic phase could be explained by the expression changes of L-PGDS (Figs. 1B and 2) . One of the features of EAE/MS is demyelination, which coincides with oligodendrocyte cell death. L-PGDS is thought to be an anti-apoptotic molecule that protects oligodendrocytes, because the oligodendrocyte apoptosis was enhanced in the brain of L-PGDS-deficient twitcher mice (39) . In human MS, L-PGDS expression was increased especially in the remyelinated lesions (40) . Thus, the decrease and the subsequent recovery of L-PGDS may be associated with the demyelination and remyelination in EAE/MS, respectively. Another PGD synthase, H-PGDS, showed the pattern opposite to L-PGDS expression (Fig.  1B) . Although H-PGDS is highly expressed in hematopoietic cells and microglia/macrophages (41), PGD 2 levels were not elevated in the SCs of EAE mice in the acute phase. Because these cells also express mPGES-1, COX-1/2 seem to prefer to functionally couple with mPGES-1 rather than H-PGDS in the cells of EAE lesions.
Contrary to the up-regulation of 5-LO/FLAP transcripts (Fig.  1B) , we demonstrated here the significant suppression of 5-LO metabolites during EAE pathology (Fig. 2) . The discrepancy be- tween transcripts and metabolites is explained by posttranscriptional/translational (such as phosphorylation) regulation of enzymes (42) (43) (44) and/or functional coupling with cPLA 2 ␣. Furthermore, COX enzymes were up-regulated in the SC around the same time (Fig. 1B) , which results in the reduction of the substrate availability for 5-LO. Emerson and LeVine reported that 5-LO Ϫ/Ϫ mice developed more severe EAE than control wild-type mice (15) , suggesting a possibility of increased PGE 2 production in the SCs of 5-LO Ϫ/Ϫ mice. Meanwhile, the report raises another possibility that lipid mediators downstream of 5-LO may play protective roles in EAE pathology. Because Gladue et al. (45) showed that a BLT1 antagonist protects mice from EAE, LTB 4 is not such a candidate for the protective lipid mediators. 5-LO generates not only LTs but also lipoxins and resolvins (46, 47) , which are anti-inflammatory/proresolving lipid mediators derived from AA and eicosapentaenoic acid, respectively, although we did not measure these lipid mediators in the current study. 12/15-LO deficiency conferred more severe EAE pathology (15), possibly because 12/15-LO also mediates lipoxin production. Resolvin E1 reduces dendritic cell migration and IL-12 production, suggesting a protective role in EAE pathology (48) . As a therapeutic strategy, blocking the hub of the AA cascade, like COX-1/2, seems to be highly effective in preventing EAE pathology. Although treatment of indomethacin actually ameliorates EAE, all mice died of gastrointestinal ulcers and bleeding (14) , a well-known side effect of NSAIDs (49) . In 2004, rofecoxib, a selective COX-2 inhibitor, was withdrawn because of an increased cardiovascular risk in patients taking the drug for Ͼ18 months (50, 51) . A possible reason why NSAIDs are currently only used for treatment of flu-like symptoms associated with IFN therapy for MS is that inhibition of COX-1/2 may put the patients at high risk for adverse effects. Therefore, it seems that targeting AA cascade downstream of COX-1/2 is highly effective in treating MS without side effects. As discussed above, components of AA cascade contribute to EAE pathology via intricate mechanisms (Fig. 5) , while our AA cascade-targeted lipidomics approach and knockout study identified the mPGES-1-PGE 2 -EPs axis as the critical pathway of AA cascade in EAE pathology. Given the function of EPs in T H 1 and T H 17 immune responses (27) (28) (29) 38 ) and our findings of mPGES-1 expression in MS lesions (Fig. 4) , inhibition of mPGES-1 has a much better chance of blocking individual EPs. Although mPGES-1 inhibitors which effectively suppress PGE 2 production in rodents (22) have not been published yet, MF63, a selective human mPGES-1 inhibitor, suppressed PGE 2 production, pyresis and inflammatory pain in knock-in mouse expressing human mPGES-1 (52) . We believe that mPGES-1 inhibitors provide a significant treatment option for MS.
Materials and Methods
Mice. Female C57BL/6 mice were purchased from Charles River for lipidomics analysis. The mPGES-1 Ϫ/Ϫ mice were generated as described in ref. 53 clustering, and correlation analyses were performed using JMP6 (SAS Institute) or Prism 4 (GraphPad). P values Ͻ0.05 were considered to be statistically significant. Quantitative Real-Time PCR. On days 11-12, 18-19, and 30-31, naive and EAE mice were anesthetized with urethane (1.5 g/kg body weight: Sigma-Aldrich) and intracardially perfused with 10 mL ice-cold PBS. The SCs were removed and total RNA was isolated using an RNeasy Mini kit (Qiagen). The purity and integrity of total RNA were determined by the absorbance at A 260/280 and gel electrophoresis, respectively. One g total RNA was reversetranscribed using SuperScript II (Invitrogen) according to the manufacturer's instructions. The RT 2 Profiler PCR Array System for eicosanoid synthesis enzymes and receptors was purchased from SuperArray (Table S3) , and quantitative RT-PCR for these components of the AA cascade was performed with a 7500 Fast Real-Time PCR system (Applied Biosystems). The relative abundance of mRNA levels in EAE mice compared with naive mice was calculated using a comparative C T method with hypoxanthine phosphoribosyltransferase as a normalization control.
Recall Responses to the MOG35-55 Peptide Antigen. LNs from mice were collected on day 11 after the first immunization and dispersed into a single cell suspension. The cells were washed and cultured for 72 h with or without MOG . For the last 8 h, 25 L [ 3 H]thymidine (1 Ci; Amersham) was added to each well. The cells were harvested onto UniFilter-GF/C glass filters (Perkin-Elmer). After the addition of MicroScint-0 scintillation mixture (Perkin-Elmer), radioactivities were determined using a TopCount microplate scintillation counter (Perkin-Elmer).
ELISA. Supernatants of LN cell culture were recovered from cell culture plates and stored at Ϫ80°C until use. Quantification of IFN-␥, TNF-␣, and IL-6 was performed using the cytometric bead array kit (BD Biosciences). IL-17 was measured with an ELISA kit (Bender MedSystems) according to the manufacturer's instructions.
Flow Cytometry. LN cells were activated for 4 h with phorbol myristate acetate and ionomycin in the presence of GolgiPlug (BD Biosciences). Cells were washed with PBS containing 0.5% BSA and fixed with 2% paraformaldehyde for 30 min. Then, cells were resuspended in 0.1% saponin in PBS containing 2 g/mL Fc block (BD Biosciences) and staining antibodies (BD Biosciences) for 30 min. FITC-anti-CD4 (clone GK1.5) and either PE-anti-IFN-␥ (clone XMG1.2) or PE-anti-IL-17 (clone TC11-18H10.1) antibodies (Abs) were used as a cell surface marker and an intracellular cytokine staining, respectively. Cells were analyzed using an EPIX XL flow cytometer (Beckman Coulter) and data were analyzed with Flow-Jo software (Treestar).
Immunohistochemistry. For murine EAE, SCs obtained from EAEinduced mice were fixed for 2 h in 4% paraformaldehyde and soaked in 20% sucrose solution in PBS. Two hours later, they were frozen in OCT (optimal cutting temperature) compound and stored at Ϫ80°C. Sections (6-m) were cut on a cryostat (Leica), blocked with 5% BSA in PBS, and stained at 4°C overnight with either anti-F4/80 (1:100; Serotec) or CD4 (1:50; BD Biosciences) Ab and mPGES-1 (1:250; Affinity BioReagents) Ab. Then, the specimens were incubated with FITC-anti-rabbit IgG (Zymed) or Alexa Fluor 568-anti-rat IgG (Molecular Probes) Ab for 2 h at room temperature. Confocal microscopy was performed with a LSM510 laserscanning microscope (Carl Zeiss).
For human MS, cerebral specimens obtained from autopsied two MS cases were used. MS #1 was a 44-year-old female with disease duration for 1 year, and MS #2 was a 31-year-old male with disease duration for 6 years. Sections were deparaffinized in xylene, rehydrated in graded alcohol, and washed in distilled water. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. Antigen retrieval was performed by autoclaving the sections in 10 mM citric acid (pH 6.0) for 10 min. The sections were washed three times in Tris-buffered saline (TBS), blocked with 5% goat serum in TBS for 30 min, and incubated at 4°C overnight with rabbit anti-human mPGES-1 polyclonal Ab (Cayman Chemical) at a 1:100 dilution or mouse anti-human CD68 monoclonal Ab (DAKO, clone KP1) at a 1:200 dilution. After three times washing with TBS, the specimens were incubated with labeled polymer of the DAKO Envision Plus System (Dako Cytomation) at room temperature for 30 min, and then rinsed with TBS. Anti-mPGES-1 antibody preabsorbed with blocking peptide (Cayman Chemical) was used as a negative control. Immunoreactivity was visualized using diaminobenzidine. Subsequently, the sections were rinsed in tap water, counterstained with hematoxylin, dehydrated with ethanol, rinsed with xylene, and mounted. For immunofluorescence imaging, the sections were washed three times in TBS containing Triton X-100 (TBST), incubated in 10 mM NH 4 Cl for 10 min and blocked with 1% BSA and 5% goat serum in TBST for 30 min. The sections were incubated at 4°C overnight with rabbit anti-human mPGES-1 polyclonal and mouse anti-human CD68 monoclonal Ab both at a 1:100 dilution. After washing with TBST, the specimens were incubated with Alexa Fluor 488 goat-anti-rabbit IgG and Alexa Fluor 594 chicken-anti-mouse IgG (Molecular Probes) at room temperature for 1 h, and then rinsed with TBS. After fluorescence labeling, the slides were immersed for 30 min in 70% ethanol supplemented with 0.1% Sudan Black B. After washing in distilled water and TBS, they were mounted and observed using a confocal laser-scanning microscope (FLUOVIEW FV300; Olympus Optical Co.). In this model, we assume that the substrate P is metabolized by metabolic pathways ''A'' and ''B'' (Left). When the pathway A maintains well balanced relations with the pathway B, the pathway A-pathway B product data points are aligned along a line, (e.g., red and blue lines; Right). The slopes of lines indicate the balances of substrate flow between two pathways and vary in accordance with the biological states (e.g., states ''X'' and ''Y''; right). If the biological state is changed from ''X'' to ''Y''; that is, the slope gets smaller, the common substrate P selectively flows into pathway B more than pathway A. Thus, the transition of the slope represents the change in the selectivity of metabolic pathway. (B) Correlations of eicosanoid levels in naive mice (light blue) and EAE mice in the induction (pink), acute (red), and chronic (orange) phases are shown (n ϭ 8 -10 animals). Each data point represents the results from a single animal. Data were analyzed statistically by Pearson's correlation and correlation parameters were shown in Table S1 . 
